[4-(benzyloxy)-2-fluorophenyl]methanol | 504414-33-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: [4-(benzyloxy)-2-fluorophenyl]methanol
• 英文别名: 4-benzyloxy-2-fluoro-benzyl alcohol；4-Benzyloxy-2-fluorobenzyl alcohol；(2-fluoro-4-phenylmethoxyphenyl)methanol
• CAS: 504414-33-9
• 化学式: C₁₄H₁₃FO₂
• 分子量: 232.254
• InChiKey: UKYCFJCEJIGXLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [4-(benzyloxy)-2-fluorophenyl]methanol 在 乙酸酐 、 二甲基亚砜 作用下， 反应 18.0h， 生成 4-苄氧基-2-氟苯甲醛
  参考文献：
  名称：

  NOVEL DIPHENYLAZETIDINONE SUBSTITUTED BY PIPERAZINE-1-SULFONIC ACID AND HAVING IMPROVED PHARMACOLOGICAL PROPERTIES

  摘要：

  因此，该发明涉及公式I的化合物或其药用可接受的盐，其药用组合物和用途。

  公开号：

  US20090264402A1
• 作为产物：
  描述：

  4-苄氧基-2-氟苯甲醛 在 sodium tetrahydroborate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 2.0h， 以95%的产率得到[4-(benzyloxy)-2-fluorophenyl]methanol
  参考文献：
  名称：

  4-[(8-Ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome P450RAI inhibitory activity

  摘要：

  公式1的化合物 1 其中，变量在说明书中定义，具有细胞色素P450RAI-1和P450RAI-2的抑制活性，适用于治疗可用视黄酸治疗的哺乳动物疾病，或由生物体的天然视黄酸控制或响应的疾病。包含本发明的化合物的制剂还可以与视黄酸和/或维生素A共同给药，以增强或延长含有视黄酸、维生素A或生物体天然视黄酸的药物的效果。

  公开号：

  US20030191181A1

文献信息

• 4-[(8-Ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome P450RAI inhibitory activity
  申请人：——

  公开号：US20030191181A1

  公开（公告）日：2003-10-09

  Compounds of Formula 1 1 wherein the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.

  公式1的化合物 1 其中，变量在说明书中定义，具有细胞色素P450RAI-1和P450RAI-2的抑制活性，适用于治疗可用视黄酸治疗的哺乳动物疾病，或由生物体的天然视黄酸控制或响应的疾病。包含本发明的化合物的制剂还可以与视黄酸和/或维生素A共同给药，以增强或延长含有视黄酸、维生素A或生物体天然视黄酸的药物的效果。
• 4-[(8-Substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-yl-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity
  申请人：——

  公开号：US20030207937A1

  公开（公告）日：2003-11-06

  Compounds of the formula 1 where the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.

  具有公式1的化合物，其中变量在说明书中定义，具有细胞色素P450RAI-1和P450RAI-2的抑制活性，并且适用于治疗可通过视黄酸治疗的哺乳动物疾病，或由生物体的天然视黄酸控制或响应的疾病。包含本发明的化合物的制剂还可以与视黄酸和/或维生素A共同给药，以增强或延长含有视黄酸、维生素A或生物体天然视黄酸的药物的效果。
• Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4<i>H</i>-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate
  作者：L. W. Lawrence Woo、Paul M. Wood、Christian Bubert、Mark P. Thomas、Atul Purohit、Barry V. L. Potter

  DOI：10.1002/cmdc.201300015

  日期：2013.5

  4‐[(4‐Cyanophenyl)(4H‐1,2,4‐triazol‐4‐yl)amino]methyl}phenyl sulfamate and its ortho‐halogenated (F, Cl, Br) derivatives are first‐generation dual aromatase and sulfatase inhibitors (DASIs). Structure–activity relationship studies were performed on these compounds, and various modifications were made to their structures involving relocation of the halogen atom, introduction of more halogen atoms,

  4-[(4-氰基苯基)(4 H -1,2,4-三唑-4-基)氨基]甲基}苯基氨基磺酸酯及其邻位卤代（F、Cl、Br）衍生物是第一代双芳香化酶和硫酸酯酶抑制剂（DASI）。对这些化合物进行了构效关系研究，并对它们的结构进行了各种修改，包括重新定位卤素原子、引入更多的卤素原子、用另一个基团替换卤素、用二氟亚甲基接头替换亚甲基接头、用其他环结构取代对氰基苯环，用咪唑基取代三唑基。发现的最有效的体外 DASI 是一种咪唑衍生物，其 IC 为50JEG-3 细胞制剂中针对芳香酶和类固醇硫酸酯酶的值分别为 0.2 和 2.5 n M。该化合物的母体酚抑制芳香酶，在同一试验中的 IC 50值为 0.028 n M。
• Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives
  申请人：Himmelsbach Frank

  公开号：US20070072813A1

  公开（公告）日：2007-03-29

  The invention relates to methods for preventing or treating metabolic disorders, for improving glycemic control, for preventing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus, for preventing or treating of complications of diabetes mellitus, for reducing the weight, for preventing or treating the degeneration of pancreatic beta cells, for treating hyperinsulinemia and insulin resistance and diabetes type 1, in patients in need thereof by administering a pharmaceutical composition comprising a pyrazole-O-glycoside as defined in claim 1, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种预防或治疗代谢性疾病的方法，改善血糖控制，预防从糖耐量受损、胰岛素抵抗和/或代谢综合征进展到2型糖尿病，预防或治疗糖尿病并发症，减轻体重，预防或治疗胰岛β细胞退化，治疗高胰岛素血症和胰岛素抵抗以及1型糖尿病，方法是通过给需要的患者口服含有在权利要求1中定义的吡唑烷-O-糖苷或其前药或其药学上可接受的盐的药物组成物。
• 4-&lsqb;(8-ETHYNYL, 8-VINYL OR 8-ETHYNYL-METHYL)-6-CHROMANOYL&rsqb;-BENZOIC AND 2-&lsqb;4-&lsqb;(8-ETHYNYL, 8-VINYL OR 8-ETHYNYL-METHYL)-6-CHROMANOYL&rsqb;-PHENYL&rsqb;-ACETIC ACID, THEIR ESTERS AND SALTS HAVING CYTOCHROME P450RAI INHIBITORY ACTIVITY
  申请人：Allergan, Inc.

  公开号：US06740676B2

  公开（公告）日：2004-05-25

  Compounds of Formula 1: wherein the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.

  式1的化合物：其中变量在规范中定义，具有细胞色素P450RAI-1和P450RAI-2的抑制活性，并适用于治疗哺乳动物的疾病，这些疾病可用视黄醇治疗，或受到或响应于生物体的本地视黄酸的控制。含有本发明化合物的制剂也可以与视黄醇和/或维生素A一起共同使用，以增强或延长含有视黄醇、维生素A或生物体本地视黄酸的药物的效果。